

1 Article

2

Characterization of collagens fibers (I, III, IV) and 3 elastin of normal and neoplastic canine prostatic 4 tissues

5 Luis Gabriel Rivera Calderón ¹, Priscila Emiko Kobayashi ² Rosemeri Oliveira Vasconcelos ¹,
6 Carlos Eduardo Fonseca-Alves ³ and Renee Laufer-Amorim ^{2,*}7 ¹ Department of Veterinary Pathology, School of Agricultural and Veterinarian Sciences, São Paulo State
8 University (Unesp), Jaboticabal, São Paulo, Brazil; lgriveramvz@gmail.com (LGRC);
9 rosemeri.vasconcelos@unesp.br (ROV)10 ² Department of Veterinary Clinic, School of Veterinary Medicine and Animal Science, São Paulo State
11 University (Unesp), Botucatu, São Paulo, Brazil; renee.laufer-amorim@unesp.br (RLA);
12 pri_kobayashi@hotmail.com (PEK)13 ³ Department of Veterinary Surgery and Anesthesiology, School of Veterinary Medicine and Animal
14 Science, São Paulo State University (Unesp), Botucatu, São Paulo, Brazil; carlos.e.alves@unesp.br

15 * Correspondence: renee.laufer-amorim@unesp.br; Tel.: +55-14-3880-2076

17 **Abstract:** This study aimed to investigate Coll-I, III, IV and elastin in canine normal prostate and
18 PC, using Picosirius red (PSR) and Immunohistochemical (IHC) analysis. Eight normal prostates
19 and 10 PC from formalin-fixed, paraffin-embedded samples were used. Collagen fibers area was
20 analyzed with ImageJ software. The distribution of Coll-I and Coll-III was approximately 80% around
21 prostatic ducts and acini, 15% among smooth muscle and 5% surrounding blood vessels, in both
22 normal prostate and PC. There was a higher median area of Coll-III in PC, when compared to normal
23 prostatic tissue ($p=0.001$ for PSR and $p=0.05$ for IHC). Immunostaining for Coll-IV was observed in
24 the basal membrane of prostate acini, smooth muscle, blood vessels, and nerve fibers of normal and
25 PC samples. Although there was no difference in Coll-IV area between normal tissue and PC, tumors
26 with Gleason score 10 showed absence of Coll-IV, when compared to scores 6 and 8 ($p=0.0095$). Elastic
27 fibers were found in the septa dividing the lobules and around the prostatic acini of normal samples,
28 and was statistically higher in PC, compared to normal tissue ($p=0.00229$). Investigation of ECM
29 components brings new information and should be correlated with prognosis in future studies.
3031 **Keywords:** dog; prostatic tissue; extracellular matrix; picosirius; immunohistochemistry

32

33

1. Introduction

34 Cancer is the second leading cause of mortality worldwide. In men, prostate cancer (PC) is the
35 third most common malignant neoplasia (after non-melanoma skin cancer and lung cancer) [1]. In
36 advanced stage, human PC often shows metastasis to bones and resistance to anti-androgen
37 treatment [2]. Similar to the men, dogs spontaneously develop PC [3, 4]. In dogs, PC it is a very
38 aggressive and highly metastatic disease [5]. Usually, bone metastasis is diagnosed at a late stage of
39 highly aggressive tumor subtypes [3]. Due to similarities in the clinical and pathologic aspects of PC
40 in both species, some authors suggest that the dogs may be considered a good model for the study of
41 human PC [4, 5, 6, 7].42 Recently, has been demonstrated in the human PC an interaction between the tumor cells and
43 the proteins of extracellular matrix (ECM). The ECM fibers play an important role in PC development
44 and progression [8, 9]. The ECM is a complex network of macromolecules [10]. The major constituents
45 of ECMs are proteoglycans and fibrous proteins (collagen, elastin, fibronectin and laminin) [11].

46 Collagen (Coll) is the most common protein of the ECM [10]. The main collagen function is to provide
47 structure, support and tensile strength, as well as, regulation of cell adhesion, chemotaxis, migration
48 and direct tissue development [12]. In some human cancers, such as breast, colon and prostate,
49 occurs a formation of abundant collagenous stroma (reactive stroma) in their tumor
50 microenvironment, responsible for the tumor metastatic process [8, 13, 14]. High density of type I
51 collagen (Coll-I) and degradation of type IV collagen (Coll-IV) are frequently observed in solid
52 cancer, associated with metastasis [9, 15-18]. In veterinary medicine, few studies were conducted to
53 understand the relationship between cancer and the collagens fibers, compared to human medicine
54 [19]. Due to the lack of information regarding tissue ECM in canine PC, this study aimed to
55 characterize and compare the composition and distribution of collagen fibers and elastin in the
56 normal prostate and canine PC, using PSR and immunohistochemical test.

57 **2. Materials and Methods**

58 *2.1. The Subjects*

59 Eight canine normal prostates and 10 PC were retrieved from the archives of the Veterinary
60 Pathology Service, FMVZ, UNESP, Botucatu, SP, Brazil. The prostates were collected from necropsies
61 from animals that had an interval between death and necropsy less than six hours. Formalin-fixed
62 paraffin-embedded (FFPE) samples from canine prostatic tissue were sectioned for histological
63 diagnosis, which was performed by three pathologists (LGRC, CEFA, PEK), at the same time, in a
64 multi-head microscopy. The histopathological classification was performed according to the human
65 WHO from Tumors of the Urinary System and Male Genital Organs [20], which was recently adapted
66 to canine PC [4]. The Gleason score was established according to Palmieri and Grieco [21]
67 (Supplementary Table 1). This study was approved by the institutional committee for the use of
68 animals in research (#10.162/2016).

69 PC samples (10/10) were from intact male dogs, with age ranging 8 up to 12 years. Six out of 10
70 samples were from mixed breed dogs, two cases (2/10) were from a German Shepherd dog, one case
71 (1/10) from a Brazilian Mastiff dog and the other one from a Poodle dog (1/10). Regarding the clinical
72 signs, five out of 10 patients showed tenesmus, three dogs had lameness (3/10) and two dogs (2/10)
73 had loss of appetite. Five out of 10 patients had metastasis at the diagnosis and all dogs (10/10) died
74 due to PC.

75 Normal samples were collected during necropsy of dogs with no clinical signs of prostatic
76 disease. All dogs (8/8) were intact male dogs with age ranging from 7 up to 11 years old. The same
77 interval between death and necropsy was used for sample collection.

78 *2.2. Picosirius (PSR)*

79 The slides were deparaffinized in xylene and rehydrated in alcohol. After, PSR staining was
80 performed using a commercial kit (HistokitTM, Easypath, SP, Brazil), according to manufacturer's
81 instructions. The slides were examined in an optical microscopy with polarized light (Axio Imager
82 A1, Zeiss®, Germany). The collagen fibers that presented red-orange birefringence were considered
83 type I, while the collagen fibers with green birefringence were interpreted as type III (Coll-III) [22].

84 *2.3. Immunohistochemistry (IHC)*

85 The slides were subject to immunohistochemical using the peroxidase method. The antibodies,
86 antigen retrieval, dilutions and incubation period are described in the Table 1. Endogenous
87 peroxidase activity was inhibited with 4% hydrogen peroxide in methanol for 10 min at room
88 temperature (RT). Then, the slides were treated with protein block serum-free for 15 min RT (Dako,
89 Carpinteria, CA, USA). In each step, the slides were washed with Tris-buffered saline (pH 7.4). A
90 LSAB system was used as secondary antibody; applied for 1 hour at RT, according to manufacturer's
91 instructions (Dako, Carpinteria, CA, USA). Peroxidase activity was revealed with 3',3'-
92 Diaminobenzidinechromogen (DAB, Substrate System, CA, Dako). For the counterstained, Harris's

93 hematoxylin was used. As negative control, primary antibodies were replaced by Tris-buffered saline
 94 solution. A canine normal skin tissue was used as positive control tissue for all antibodies.
 95

96 **Table 1.** Primary antibodies, retrieval antigen, dilution and incubation period used in the IHC test.

Primary antibody	antigen Retrieval	Dilution	Incubation Period
Collagen I, rabbit, Novotec	Citrate buffer pH 6,0, microwave, twice for 5 min	1:1000	Overnight at 4°C
Collagen III, rabbit, Novotec	Pepsin 2%, pH 1,4 in oven for 10 min at 60°C after for 30 min at 37°C.	1:1000	Overnight at 4°C
Collagen IV, rabbit, Biorbyt	Pepsin 2%, pH 1,4, in oven for 10 min at 60°C after for 30 min at 37°C.	1:1000	Overnight at 4°C
Elastin (BA-4), mouse, Santa Cruz.	Citrate buffer pH 6,0, pressure cooker (Pascal®, Dako, Carpinteria, CA, USA)	1:100	Overnight at 4°C

97

98 *2.4. Interpretation of PSR and IHC staining*

99 In the PC samples, areas with a higher percentage of neoplastic cells and minimal density of
 100 inflammatory cells were selected. In the normal samples, it was collected samples from the peripheral
 101 region of the prostatite gland, avoiding areas close to the median septa, according to Ruetten et al.
 102 [23]. For normal and PC samples, it was captured five fields (20x magnification) with a digital camera
 103 (Axioncam MRc, Zeiss® Vision, Germany) for each protein and technique (IHC and PSR). The stained
 104 areas were analyzed with Image J 1.49v software (National Institutes of Health, USA) and were
 105 assessed by setting a threshold, using the Image J threshold tool in accordance with the procedure
 106 described by Bauman et al., [24]. Briefly, the staining distribution and intensity of the collagens and
 107 elastic fibers were evaluated in both normal canine prostate and PC. For PSR staining, it was used a
 108 manual thresholding of hue (121-179), saturation (20-255), and brightness (10-255) values in ImageJ
 109 [24]. For each marker in immunohistochemistry, we established a threshold values as follow: Coll-I:
 110 hue (0-170), saturation (69-255), and brightness (90-181), Coll-III: hue (111-176), saturation (10-98),
 111 and brightness (37-157), Coll-IV: hue (65-255), saturation (90-178), and brightness (101-255) and
 112 elastin: hue (0-146), saturation (0-175), and brightness (0-209).

113 *2.5. Data analysis*

114 Descriptive statistics was used to define the median and percentile of Coll-I, Coll-III and elastin
 115 in normal and canine PC. For statistical propose, we grouped samples with Gleason score 6 and 8
 116 and compared with samples with Gleason score 10. Mann-Whitney U test was applied to compare
 117 the area percentage among normal and canine PC. Statistical significance was set at $p \leq 0.05$. All
 118 statistical analysis was done using GraphPad Prism 8 (GraphPad Software Inc. La Jolla, CA).

119 **3. Results**

120 Five out of 10 PC samples had Gleason 8 (5/10), four had Gleason score 10 (4/10) and one Gleason
 121 score 6 (1/10). The mean survival time was 152.1 days (± 134.8). All prostatic samples (18/18) stained
 122 with PSR and the Coll-I was more abundant than Coll-III (Figure 1). The median expression of Coll-
 123 I by PSR in normal samples was 1.89 (1.196 - 3.839) and in PC samples was 2.24 (1.358 - 2.834). There
 124 was no statistical difference of Coll-I expression between normal and PC samples. Regarding the IHC
 125 for Coll-I, we also identified a higher proportion of Coll-I compared to Coll-III (Figure 1). The median
 126 expression of Coll-I in normal samples by IHC was 4.73 (1.367 - 8.414) and 6.18 (1.577 - 17.572) for
 127 PC samples. We identified a positive correlation of Coll-I expression between PSR and IHC techniques
 128 ($R=0.6185$; $P=0.05$). Thus, although the results are numerically different for both techniques, there is
 129 a correlation of the results. Besides that, we evaluated the distribution of the Coll-I thought the
 130 normal prostate. Approximately 80% of the Coll-I was located surrounding prostatic ducts and acini,
 131 15% among smooth muscle and 5% around blood vessels (Figure 1). We also did not find statistical

132 difference of Coll-I immunoexpression between normal and PC samples. Comparing Coll-I
 133 expression between samples with Gleason score 10 and 8/6, we did not find statistical difference
 134 ($P=0.761$)

135 Regarding Coll-III expression, we identified positive stain in all prostatic samples (18/18) for
 136 both techniques. PC samples showed a higher expression of Coll-III than normal samples by PSR
 137 ($P=0.001$) and IHC ($p=0.05$). The median expression for Coll-III expression in normal samples was
 138 1.64 (0.975 – 3.329) and 2.25 (1.067 – 3.605) for PC samples, using PSR. We identified a strong positive
 139 correlation ($R=0.7805$; $P=0.007$) of Coll-III expression between PSR and IHC techniques. Thus,
 140 samples with high Coll-III by PSR technique also showed a higher Coll-III expression by IHC. We also
 141 qualitatively assessed the Coll-III distribution among the prostatic tissues. In both normal and PC
 142 samples, 80% of the Coll-III was located surrounding prostatic ducts and acini, 15% among smooth
 143 muscle and 5% around blood vessels (Figure 1). Table 2 shows the median, 25% percentile and 75%
 144 percentile values of Coll-I and Coll-III according to the diagnosis group and test applied. There was
 145 no statistical difference regarding the Coll-III expression and the Gleason scores ($P=0.0654$).
 146

147 **Table 2.** Median, 25% percentile and 75% percentile values of area percentage staining for Coll-I and
 148 Coll-III in the normal and canine PC, according to the method used.

	PSR test				IHC test				
		25%	Median	75%	p	25%	Median	75%	p
Coll-I	N	1.25	1.89	2.27		2.85	4.73	8.03	
	PC	2.09	2.24	2.43	0.1298	3.31	6.18	8.56	0.3159
Coll-III	N	1.33	1.64	2.06		1.81	3.22	5.03	
	PC	1.68	2.25	3.11	0.001	3.72	5.07	6.44	0.05


149 Coll-I: Collagen I, Coll-III: Collagen III, N: Normal, PC: Prostatic carcinoma.

150
 151 Immunostaining for Coll-IV was observed in the basal membrane (BM) of prostate acini, smooth
 152 muscle, blood vessels, and never fibers of normal and PC samples, although it was discontinuous in
 153 BM (Figure 2). It was observed a Coll-IV immunostaining surrounding continuously the blood
 154 vessels in both normal and PC samples. The distribution of Coll-IV was approximately 70% in the
 155 BM, 15% in smooth muscle, 10% in blood vessels BM and 5% in nerve fibers in both groups. When
 156 we compared the normal prostate with PC samples, we did not find statistical difference, concerning
 157 Coll-IV expression ($P=0.2135$). However, it was identified absence of Coll-IV immunostaining in the
 158 tumors with Gleason score 10 compared to tumors with Gleason score 6 and 8 ($P=0.0095$) (Figure 2).
 159 The results of Coll-IV expression are described in Table 3.
 160

161 **Table 3.** Median, 25% percentile and 75% percentile values of area percentage staining for Coll-IV
 162 and elastin in the normal prostate and canine PC samples.

	Group	IHC test			
		25%	Median	75%	P
Coll-IV	Normal	1.11	1.41	1.72	0.2135
	PC	0.58	1.14	1.61	
Elastin	Normal	0.25	0.26	0.42	0.00229
	PC	0.28	0.43	0.51	

163
 164 Immunostaining for elastin was observed with similar distribution than Coll-IV, around blood
 165 vessels in normal tissues and PC. Elastic fibers were found in the septa dividing the lobules and
 166 around the prostatic acini of normal samples. A high amount of elastic fibers was observed around
 167 the ducts and the urethra in normal and canine PC (Figure 2). It was identified a higher expression
 168 of Elastin in PC samples compared to normal samples ($P=0.00229$). There was no statistical
 169 difference comparing Gleason score 10 with Gleason 6 and 8 samples ($P=0.897$).



170

171


172

173

174

175

Figure 1. The immunohistochemistry and PSR stain in normal tissue and canine PC. a: immunostaining of Coll-I in the stroma of normal prostate (case No. 3). b: immunostaining of Coll-III in the stroma of the normal prostatic tissue (case No. 3). c: PSR staining observed in an optical microscopy with polarized light, the collagens fibers present red-orange birefringence (Coll-I) and green birefringence (Coll-III) in a smaller amount (case No. 3). d: immunostaining of Coll-I in the stroma of prostatic neoplastic tissue (case No. 11). e: immunostaining of Coll-III in the stroma of canine PC (case No. 11). f: PSR staining in the canine PC with similar amounts of Coll-I and Coll-III (case No. 11).



176
 177 **Figure 2.** Immunostaining for Coll-IV and elastin in canine prostatic tissue. a: Coll-IV immunostaining
 178 in the basal membrane of canine PC with cribiforme pattern (case No. 15). b: Absence of Coll-IV
 179 immunostaining in canine PC with solid pattern (case No. 12). c: Elastin fibers around the prostatic
 180 acini of normal samples (case No. 5). d. High amount of elastin fibers around the urethra (case No. 5).

181 **4. Discussion**

182 Changes in the cellular interactions, between the stroma and epithelial cells, play a crucial role
 183 in the carcinogenic process and progression of different human neoplasms such as prostate, breast
 184 and colon [24-27]. In cancer, the EMC is a network of macromolecules that allows the cellular
 185 evasion towards the defense of the organism, besides helping in their metastatic process [10].
 186 Collagens fibers are important components of ECM remodeling the tumor microenvironment, and is
 187 known that their degradation and redeposition promote tumor infiltration, angiogenesis, invasion and
 188 migration [11]. ECM pattern changes throughout tumor initiation and clinical disease, and it also
 189 influences cancer cell behavior and abilities to proliferate and metastasizes [28].

190 In this study, we identified and characterized collagen and elastin fibers in the normal prostate
 191 and canine PC (inside the tumor) using PSR and IHC tests. We also compared the correlation of both
 192 tests to identify Coll-I and III expression. Coll-I expression was not statistically different when
 193 compared normal prostates and canine PC samples using both techniques. Although PSR is less
 194 sensitive for staining of collagen fibers, the positive correlation between these two techniques, allows
 195 us to suggest that PSR is cheaper and routinely used in some histology laboratories, and can be a
 196 good choice. In humans, Bauman et al., [29] evaluated the Coll-I content in normal prostates and
 197 benign prostatic hyperplasia (PH) by PSR staining, with no statistical difference. We did not find
 198 studies evaluating collagen fibers with PSR and IHC simultaneously, in both human and canine PC.
 199 Regarding the immunostaining of Coll-I, statistical difference was also not identified comparing
 200 normal and PC samples. However, in PC samples, we identified a higher median of Coll-I expression.
 201 The lack of statistical difference can be related to the low number of cases and it also corroborates
 202 with Bauman et al., [29] results.

203 Wegner et al., [30] performed a study with PSR in the prostate gland of C57BL/6J mice. They
 204 found that fluorescent PSR imaging was more sensitive than polarized light for identify the collagen

205 fibers. In addition, Fluorescent PSR imaging was compatible with the collagen expression by IHC
206 test. The fluorescent PSR imaging method seems to be promising, but it must still be studied in the
207 comparative oncology. Fewer studies with FFPE samples of canine tumors were conducted to analyze
208 the collagens fibers by PSR [19, 31, 32]. Bedoya et al., [33] used PSR staining in canine squamous cell
209 carcinomas (SCCs), classified in well and poorly differentiated. The percentage of Col-I was
210 approximately 30% for low- and high-grade SCCs. Their results showed higher percentage of
211 collagen fibers than observed in our study, comparing normal and canine PC, but these are different
212 tumors, with different patterns and locations.

213 The interaction between the EMC components and metastatic progression is widely studied in
214 human cancers. However, the literature lack information regarding the collagen fibers and elastin
215 expression in human and canine PC tissues. The previous human literature is focused on the role of
216 EMC components in prostate cancer cells [34, 35], instead of human prostatic tissue [36, 37]. The Type
217 I collagen degradation product (ICPT) was previously investigated in human PC, predicting bone
218 metastasis [36]. However, ICPT expression is evaluated in serum and these authors did not evaluated
219 collagen I expression in the prostatic samples. In this study, we evaluated the Coll-I
220 immunoexpression in normal and neoplastic prostates, and did not study metastatic disease, which
221 could be an interesting information.

222 Coll-I and III gene and protein expression were previously evaluated in human PC, using RT-
223 qPCR and IHC [38]. These authors also correlated Coll-I expression with Gleason score. No
224 correlation was found between protein and gene expression for both collagens. However, the IHC
225 analysis showed that Coll-I and Coll-III was significantly reduced in PC, in all Gleason scores, when
226 compared to benign areas. In our work, we found higher Coll-I and Coll-III expression in PC,
227 compared to normal prostatic tissue by PSR and IHC tests, but only Col-III expression was
228 significantly different. This is an opposite result, compared to Duarte et al. [38].

229 One explanation for lower Coll-I and Coll-III found by Duarte et al. [38] is that collagen reduction
230 in PC could be the result from high metalloproteinase (MMP) activity [38]. MMPs have been
231 correlated with tissue invasion and tumor progression of different cancers [45]. In human PC, tissue
232 inhibitors of matrix metalloproteinases (TIMPs) and MMPs dysregulation are caused by a significant
233 gain of MMP-2 and 9 expression and TIMP-1 loss. The increased MMP-2 and 9 expression leads to
234 the degradation of collagen fibers being the evaluation of Coll-I expression tricky. In canine PC,
235 MMP-2 and MMP-9 were previously evaluated and the authors found overexpression, when
236 compared PC to normal prostate. However, the authors did not compare the results with collagen
237 expression [46], as well as we did not measure MMPs in the present study. Based on this previous
238 description in canine PC [45], MMP-2 and 9 overexpression can induce collagen degradation
239 interfering in the collagen evaluation by IHC and PSR. EMC is generated in the microenvironment
240 dynamically, according to physiological and pathological conditions (for example: age, hormone
241 deprivation, inflammation, tumor progression and others). Our results represent a specific moment
242 of the tumor, and not the dynamic protein expression in different tumor phases, such as growth,
243 progression and invasion. Hypothetically, future biopsies could show higher MMP expression and
244 lower Collagen expression.

245 Concerning Coll-I and III role in cancer, there are evidences that the stiffness of the
246 microenvironment facilitates invasion and migration [42]. Epithelial cancer cells can migrate and
247 invade basal membrane and surrounding stroma easily, in an environment rich with collagen fibers
248 [43]. Also, higher collagen concentration can stimulate epithelial tumor cell to undergo epithelial-
249 mesenchymal transition (EMT), corroborating with the malignant and metastatic potential [44]. So, it
250 is not surprising that canine PC had higher Coll-I and III area than normal prostatic tissue, and we
251 had 5/10 (50%) of the dogs with metastatic disease.

252 In a study measuring a Coll-I metabolite (N-terminal telopeptide – NTx) in serum from human
253 patients with PC, this protein was correlated with tumor biochemical recurrence, stage of disease and
254 bone metastasis [39]. Thus, we can assume that in a group of non-metastatic tumors, Coll-I might not
255 have an important role, as in metastatic PC. We compared tumor with metastasis at the diagnosis

256 (N=5) versus non-metastatic tumors regarding all markers (data not shown). However, we did not
257 find statistical difference between both groups, probably due the low number of samples.

258 A previous study evaluated the difference in Coll-I expression “*in vitro*” in PC cells derived from
259 bone marrow (bone metastasis PC cells) and from other metastatic tissues [40]. This study
260 demonstrated a cellular reorganization (alterations in adhesion, elasticity and cytoskeletal
261 organization) mediated by Coll-I and fibronectin [40]. The ECM expression is dynamic through the
262 tumor life [41], so, maybe, when gaining metastatic abilities, Coll-I could be even higher than normal
263 tissue, or our results could present the initiation of a metastatic phenotype.

264 Coll-IV was slightly decreased in canine PC, when compared to normal prostatic tissue, with
265 no statistical difference. Since most of Coll-IV fibers was concentrated in the BM in both PC and
266 normal tissue, the difference found is mainly related to this layer. It is expected to find reduced Coll-
267 IV in the BM of neoplastic acinus, since this is a hallmark of carcinomas [27]. Coll-IV, in the BM is not
268 just a scaffold for the epithelial and endothelial cells, it also modulates cellular differentiation and
269 proliferation [42]. Changes in Coll-IV can contribute to cancer progression, by leading to changes in
270 cell polarity, proliferation, invasiveness and survival [47].

271 When BM, surrounding epithelial cancer cells, is lacking, it allows cancer cells to directly interact
272 with stromal components, specially cancer associate fibroblasts (CAFs), changing not only the tumor
273 cell behavior, but also the cancer microenvironment [48]. Concerning Gleason grade and Coll-IV
274 expression, tumors with higher Gleason grade (10) showed absence of Coll-IV, compared to scores
275 6/8. Babichenko et al. [49] found that Coll-IV fibers disappeared with the increase of Gleason score.
276 They also reported less Coll-IV immunoexpression in PC, compared to PH.

277 The pattern of Col-IV expression in this study was similar to normal human prostate and PC
278 [49]. An interesting finding was that solid canine PC had lower/absent Coll-IV expression than other
279 PC patterns and normal tissues. Sinha et al., [50] found that Coll-IV immunostaining was less uniform
280 or absent in the BM of poorly-differentiated human PC when compared to well-differentiated PC,
281 HBP and normal human prostates. Similar results were also observed in feline and canine mammary
282 tumors as well as in canine hemangiosarcoma [31, 32]. In an experimental study of gerbil model of
283 prostate carcinogenesis, the authors found proteolytic degradation of Coll-IV in a patchy pattern in
284 the acini, indicating BM rupture [51].

285 We found a normal pattern [52] of elastic fibers in canine prostate (in the septa dividing the
286 lobules, around the alveoli, ducts and the urethra). The interesting result was that canine PC, had a
287 statistical higher median of elastin fibers ($p=0.00229$) than normal tissue. Elastin fibers are involved
288 in tumor invasion and metastasis [53], cell proliferation, adhesion, apoptosis and angiogenesis [54].

289 There is an important cross talk between elastic fiber peptides and cells like fibroblast (CAFs),
290 lymphocytes, macrophages, smooth muscle and endothelial cells (tumor microenvironment), acting
291 as a pro-tumorigenic protein [55]. There are no reports of elastin fibers and prostatic cancer in
292 different species, so the biological role of the increase of elastic fibers should be further investigated.

293 The collagen and elastin patterns in the prostate gland are dynamic and important differences
294 can be found in different species. Besides that, the prostate gland anatomy, the animal breed, age and
295 castration status can lead in different collagen and elastin fiber patterns [23]. In this study, we lack
296 information regarding the region of the prostate gland (periurethral, peripheral or of the prostate
297 biopsy) that the tissue specimens were collected. Thus, we strongly recommend the annotation of
298 each region that the prostatic tissue was collected before evaluating the EMC components in canine
299 prostate.

300 This study brings new information to veterinary literature, concerning some ECM components
301 from canine PC. There are some points that could have been addressed, such as carcinoma
302 surrounding fibrous tissue measurement, study of the metastasis and correlation with prognosis, so
303 there is still a gap to be fulfill.

304

305 5. Conclusions

306 PSR and IHC teste have a similar role in the evaluation of distribution and percentage area of
307 collagen in normal and neoplastic canine prostate. There is a change in ECM profile in canine PC,
308 with higher collagen III and elastin fiber expression in PC, compared to normal canine tissue.
309 Collagen IV higher expression correlates with higher Gleason scores in canine PC, so the investigation
310 of ECM components brings new information and should be correlated with prognosis in future
311 studies.

312 **Supplementary Materials:** The following are available online at www.mdpi.com/xxx/s1, Table S1: Histological
313 type of 10 canine prostatic carcinomas, according to Eble et al., 2004 and Palmieri et al., 2014.

314 **Author Contributions:** Conceptualization, L.G.V.C., C.E.F.A. and R.L.A.; methodology, L.G.R.C. and P.E.K.;
315 formal analysis, L.G.R.C. and C.E.F.A.; investigation, L.G.R.C. and C.E.F.A.; resources, R.L.A.; data curation,
316 L.G.R.C., C.E.F.A. and R.L.A.; writing—original draft preparation, L.G.R.C.; writing—review and editing,
317 C.E.F.A., P.E.K., R.O.V. and R.L.A.; supervision, R.O.V. and R.L.A.; project administration, C.E.F.A.X.X.; funding
318 acquisition, R.L.A. and C.E.F.A.

319 **Funding:** This research was funded by National Council for Scientific and Technological Development - CNPq,
320 grant number 443884/2014-5 and 422139/2018-1.

321 **Conflicts of Interest:** The authors declare no conflict of interest.

322 References

- 323 1. Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D.,
324 Bray, F. Cancer incidence and mortality worldwide: Source, methods and major patterns in GLOBOCAN
325 2012. *Int. J. Cancer.* **2014**, *136*. doi: 10.1002/ijc.29210.
- 326 2. Mundy, G. Metastasis to bone: causes, consequences and therapeutic opportunities. *Nat. Rev. Cancer.* **2002**, *2*,
327 584-593. DOI: 10.1038/nrc867.
- 328 3. Leroy, B. R., Northrup N. Prostate cancer in dogs: comparative and clinical aspects. *Vet. J.* **2009**, *180*, 149-162.
329 DOI: 10.1016/j.tvjl.2008.07.012
- 330 4. Palmieri, C., Lean, F. Z., Akter, S. H., Romussi, S., Grieco, V. A retrospective analysis of 111 canine prostatic
331 samples: histopathological findings and classification. *Res. Vet. Sci.* **2014** *97*, 568-73. DOI:
332 10.1016/j.rvsc.2014.11.006
- 333 5. Argyle, D. J. Prostate cancer in dogs and men: unique opportunity to study the disease. *Vet. J.* **2009**, *180*, 137-
334 138. DOI: 10.1016/j.tvjl.2008.08.012.
- 335 6. Palmieri, C., Grieco, V. (2015). Proposal of Gleason-like grading system of canine prostate carcinoma in
336 veterinary pathology practice. *Research and Veterinary Science*, *103*, 11-15. doi: 10.1016/j.rvsc.2015.09.004.
- 337 7. Fonseca-Alves CE, Kobayashi PE, Rivera Calderón LG, Felisbino SL, Rinaldi JC, Drigo SA, Rogatto SR, Laufer-
338 Amorim R. Immunohistochemical panel to characterize canine prostate carcinomas according to aberrant
339 p63 expression. *PLoS One.* **2018**, *12*(13)(6):e0199173. DOI: 10.1371/journal.pone.0199173.
- 340 8. Palumbo, A. Jr., Ferreira, L. B., Reis de Souza, P. A., Oliveira, F. L., Pontes, B., Viana, N. B., Machado, D.
341 E., Palmero, C. Y., Alves L. M., Gimba, E. R., Nasciutti, L. E. Extracellular matrix secreted by reactive stroma
342 is a main inducer of pro-tumorigenic features on LNCaP prostate cancer cells. *Cancer Lett.* **2012**, *321*, 55-64.
343 DOI: 10.1016/j.canlet.2012.02.026
- 344 9. Penet, M. F., Kakkad, S., Pathak, A. P., Krishnamachary, B., Mironchik, Y., Raman, V., Solaiyappan, M.,
345 Bhujwalla, Z. M. Structure and function of prostate cancer dissemination-permissive extracellular matrix.
346 *Clin Cancer Res.* **2016**, *23*, 2245-2254. DOI: 10.1158/1078-0432.CCR-16-1516.
- 347 10. Frantz, C., Stewart, K. M., Weaver, V. M. The extracellular matrix at a glance. *J. Cell. Sci.* **2010**, *123*, 4195-4200.
348 DOI: 10.1242/jcs.023820.
- 349 11. Theocharis, A. D., Skandalis, S. S., Gialeli, C., Karamanos, N. K. (2016). Extracellular matrix structure. *Adv.
350 Drug Deliv. Rev.* **2016**, *97*, 4-27. DOI: 10.1016/j.addr.2015.11.001.
- 351 12. Rozario, T., DeSimone, D. W. (2010). The extracellular matrix in development and morphogenesis: a dynamic
352 view. *Developmental Biology*, *341*, 126-140. doi: 10.1016/j.ydbio.2009.10.026.
- 353 13. Tuxhorn, J. A., Ayala, G. E., Rowley, D. R. (2001). Reactive stroma prostate cancer progression. *The journal
354 of the urology*, *166*, 2472-2483.

355 14. Zhang, K., Corsa, C. A., Ponik, S. M., Prior, J. L., Piwnica-Worms, D., Eliceiri, K. W., Keely, P. J., Longmore,
356 G. D. (2013). The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer
357 metastasis. *Nature cell biology*, **15**, 677-687. doi: 10.1038/ncb2743.

358 15. Zeng, Z. S., Cohen, A. M., Guillem, J. G. (1999). Loss of basement membrane type IV collagen is associated
359 with increased expression of metalloproteinases 2 and 9 during human colorectal tumorigenesis.
360 *Carcinogenesis*, **20**, 749-755.

361 16. Tanjore, H., Kalluri, R. (2006). The role of type IV collagen and basement membranes in cancer progression
362 and metastasis. *American Journal of Pathology*, **168**, 715-717. doi: 10.2353/ajpath.2006.051321.

363 17. Provenzano, P. P., Inman, D. R., Eliceiri, K. W., Knittel, J. G., Yan, L., Rueden, C. T., White, J. G., Keely, P. J.
364 (2008). Collagen density promotes mammary initiation and progression. *BMC Medicine*, **28**:6:11. doi:
365 10.1186/1741-7015-6-11.

366 18. Li, A., Zhou, T., Guo, I., Si, J. (2010). Collagen type I regulates β -catenin tyrosine phosphorylation and nuclear
367 translocation to promote migration and proliferation of gastric carcinoma cells. *Oncology Reports*, **23**, 1247-
368 1255.

369 19. Case, A., Brisson, B. K., Durham, A. C., Rosen, S., Monslow, J., Buza, E., Salah, P., Gillem, J., Ruthel, G.,
370 Veluvolu, S., Kristiansen, V., Puré, E., Brown, D. C., Sørenmo, K. U., Volk, S. W. (2017). Identification of
371 prognostic collagen signatures and potential therapeutic stromal targets in canine mammary gland
372 carcinoma. *PLoS One*, **12**, e0180448. doi: 10.1371/journal.pone.0180448.

373 20. Eble, J. N., Sauter, G., Epstein, I. A. *SesterhennPathology and genetics of tumours of the urinary system and*
374 *male genital organs*. International Agency for Research on Cancer, Lyon, France, 2004.

375 21. Palmieri C, Grieco V. Proposal of Gleason-like grading system of canine prostate carcinoma in veterinary
376 pathology practice. *Res Vet Sci.* 2015 Dec;103:11-5.

377 22. Coleman, R. (2011). Picrosirius red staining revisited. *Acta Histochemica*, **113**, 231-233. doi:
378 10.1016/j.acthis.2010.02.002.

379 23. Ruetten, H., Wegner, K.A., Romero, M.F., Wood, M.W., Marker, P.C., Strand, D., Colopy, S.A., Vezina, C.M.
380 (2018) Prostatic collagen architecture in neutered and intact canines. *Prostate*. **78**(11), 839-848. doi:
381 10.1002/pros.23641.

382 24. Martin M, Pujuguet P, Martin F. (1996). Role of stromal myofibroblasts infiltrating colon cancer in tumor
383 invasion. *Pathol Res Pract.* **192**(7):712-7.

384 25. Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR. (2005). Stromal expression of connective
385 tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. *Cancer Res.* **1**;65(19):8887-
386 95.

387 26. Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR. (2002). Stromal cells promote angiogenesis and
388 growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. *Cancer Res.*
389 **1**;62(11):3298-307.

390 27. Valastyan S, Weinberg RA. (2011). Tumor metastasis: molecular insights and evolving paradigms. *Cell*.
391 **14**;147(2):275-92. doi: 10.1016/j.cell.2011.09.024.

392 28. Jones CE, Hammer AM, Cho Y, Sizemore GM, Cukierman E, Yee LD, Ghadiali SN, Ostrowski MC, Leight JL.
393 (2019). Stromal PTEN Regulates Extracellular Matrix Organization in the Mammary Gland. *Neoplasia*.
394 **21**(1):132-145. doi: 10.1016/j.neo.2018.10.010.

395 29. Bauman, T. M., Nicholson, T. M., Abler, L. L., Eliceiri, K. W., Huang, W., Vezina, CM., Ricke, W. A. (2014).
396 Characterization of fibrillar collagens and extracellular matrix of glandular benign prostatic hyperplasia
397 nodules. *PLoS One*, **9**, e109102. doi: 10.1371/journal.pone.0109102.

398 30. Wegner, K. A., Keikhosravi, A., Eliceiri, K. W., Venzina C. M. (2017). Fluorescence of picrosirius red
399 multiplexed with immunohistochemistry for the quantitative assessment of collagen in tissue sections. *The*
400 *journal of histochemistry and cytochemistry*, **65**, 8, 479-490.

401 31. Benazzi, C., Sarli, G., Galeotti, M., Marcato, P. S. (1993). Basement membrane components in mammary
402 tumours of the dog and cat. *Journal of comparative pathology*, **109**, 3, 241-252.

403 32. Murakami, M., Sakai, H., Kodama, A., Yanai, T., Mori, T., Maruo, K., Masegi, T. (2009). Activation of matrix
404 metalloproteinase (MMP-2) by membrane type 1-MMP and abnormal immunolocalization of the basement
405 membrane components laminin and type IV collagen in canine spontaneous hemangiosarcomas. *Histology*
406 and *Histopathology*, **24**, 437-446. doi: 10.14670/HH-24.437.

407 33. Bedoya, S.A.O., Conceição, L.G., Viloria, M.I.V., Loures, F.H., Valente, F.L., Amorim, R.L., & Silva, F.F. (2016).
408 Caracterização de colágenos tipos I e III no estroma do carcinoma de células escamosas cutâneo em
409 cães. Arquivo Brasileiro de Medicina Veterinária e Zootecnia, 68(1), 147-154.

410 34. Koutsilieris, M., Sourla, A., Pelletier, G., Doillon, C.J. (1994) Three-dimensional type I collagen gel system for
411 the study of osteoblastic metastases produced by metastatic prostate cancer. *J Bone Miner Res.* 9(11), 1823-
412 32.

413 35. Hall, C.L., Dai, J., van Golen, K.L., Keller, E.T., Long, M.W. Type I collagen receptor (alpha 2 beta 1) signaling
414 promotes the growth of human prostate cancer cells within the bone. *Cancer Res.* 2006 Sep 1;66(17):8648-
415 54.

416 36. Kymlä, T., Tammela, T.L., Risteli, L., Risteli, J., Kontturi, M., Elomaa, I. (1995). Type I collagen degradation
417 product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate
418 cancer. *Br J Cancer.*, 71(5), 1061-4.

419 37. Burns-Cox, N., Avery, N.C., Gingell, J.C., Bailey, A.J. (2001). Changes in collagen metabolism in prostate
420 cancer: a host response that may alter progression. *J Urol.*, 166(5), 1698-701.

421 38. Duarte, A. H., Colli, S., Alves-Pereira, J. L., Martins, M. P., Sampaio, F. J. B., Ramos, C. F. (2012). Collagen I
422 and III metalloproteinase gene and protein expression in prostate cancer in relation to Gleason score.
423 *International Braz J Urol.*, 38, 341-354.

424 39. Jablonka F, Alves Bda C, de Oliveira CG, Wroclawski ML, Szwarc M, Vitória W de O, Fonseca F, Del Giglio
425 A. (2014). Serum crosslinked-N-terminal telopeptide of type I collagen (NTx) has prognostic implications
426 for patients with initial prostate carcinoma (PCa): a pilot study. *Clin Chim Acta.* 25;436:316-8. doi:
427 10.1016/j.cca.2014.06.025.

428 40. Docheva D, Padula D, Schieker M, Clausen-Schaumann H. (2010). Effect of collagen I and fibronectin on the
429 adhesion, elasticity and cytoskeletal organization of prostate cancer cells. *Biochem Biophys Res Commun.*
430 12;402(2):361-6. doi: 10.1016/j.bbrc.2010.10.034.

431 41. Kai F, Laklai H, Weaver VM. (2016). Force Matters: Biomechanical Regulation of Cell Invasion and Migration
432 in Disease. *Trends Cell Biol.* 26(7):486-497. doi: 10.1016/j.tcb.2016.03.007.

433 42. Timpl R. (1996). Macromolecular organization of basement membranes. *Curr Opin Cell Biol.* 8(5):618-24.

434 43. Cassereau L, Miroshnikova YA, Ou G, Lakins J, Weaver VM. (2015). A 3D tension bioreactor platform to
435 study the interplay between ECM stiffness and tumor phenotype. *J Biotechnol.* 10;193:66-9. doi:
436 10.1016/j.jbiotec.2014.11.008.

437 44. Haage A, Schneider IC. (2014). Cellular contractility and extracellular matrix stiffness regulate matrix
438 metalloproteinase activity in pancreatic cancer cells. *FASEB J.* 28(8):3589-99. doi: 10.1096/fj.13-245613.

439 45. Brehmer, B., Biesterfeld, S., Jakse, G. (2003). Expression of matrix metalloproteinases (MMP-2 and -9) and
440 their inhibitors (TIMP-1 and -2) in prostate cancer tissue. *Prostate Cancer Prostatic Dis.*, 6(3), 217-22.

441 46. Faleiro, M. B., Croce, G. B., Toledo, D. C., Rodrigues, M. M., Batista, A. C., Damasceno, A. D., Brito, L. A.,
442 Laufer-Amorim, R., De Moura, V. M. (2013). Matrix metalloproteinases 2 and 9 expression in canine normal
443 prostate and with proliferative disorders. *Ciência Rural*, 43, 6. doi: 10.1590/S0103-84782013005000050.

444 47. Bissell MJ, Hines WC. (2011). Why don't we get more cancer? A proposed role of the microenvironment in
445 restraining cancer progression. *Nat Med.* 17(3):320-9. doi: 10.1038/nm.2328.

446 48. Miyazaki K, Oyanagi J, Hoshino D, Togo S, Kumagai H, Miyagi Y. (2019). Cancer cell migration on elongate
447 protrusions of fibroblasts in collagen matrix. *Sci Rep.* 22;9(1):292. doi: 10.1038/s41598-018-36646-z.

448 49. Babichenko II, Andriukhin MI, Pulbere S, Loktev A. (2014). Immunohistochemical expression of matrix
449 metalloproteinase-9 and inhibitor of matrix metalloproteinase-1 in prostate adenocarcinoma. *Int J Clin Exp
450 Pathol.* 1;7(12):9090-8.

451 50. Sinha, A. A., Gleason, D. F., DeLeon, O. F., Wilson, M. J., Limas, C., Reddy, P. K., Furcht, L. T. (1991).
452 Localization of type IV collagen in the basement membranes of human prostate and lymph nodes by
453 immunoperoxidase and immunoalkaline phosphatase. *Prostate*, 18, 2, 93-104.

454 51. Gonçalves BF, Campos SG, Costa CF, Scarano WR, Góes RM, Taboga SR. (2015). Key participants of the tumor
455 microenvironment of the prostate: an approach of the structural dynamic of cellular elements and
456 extracellular matrix components during epithelial-stromal transition. *Acta Histochem.* 117(1):4-13. doi:
457 10.1016/j.acthis.2014.10.009.

458 52. Maretová, E. (2017). Immunohistochemical localization of elastic system fibres in the canine prostate. *Folia
459 Veterinaria*, 6, 1,5-10. doi: 10.1515/fv-2017-0001.

460 53. Krušlin B, Ulamec M, Tomas D. Prostate cancer stroma: an important factor in cancer growth and
461 progression. *Bosn J Basic Med Sci.* 2015 May 13;15(2):1-8. doi: 10.17305/bjbm.2015.449.

462 54. Scandolera A, Odoul L, Salesse S, Guillot A, Blaise S, Kawecki C, Maurice P, El Btaouri H, Romier-Crouzet
463 B, Martiny L, Debelle L, Duca L. The Elastin Receptor Complex: A Unique Matricellular Receptor with
464 High Anti-tumoral Potential. *Front Pharmacol.* 2016 Mar 4;7:32. doi: 10.3389/fphar.2016.00032.

465 55. Fülöp T, Larbi A. (2002). Putative role of 67 kDa elastin-laminin receptor in tumor invasion. *Semin Cancer
466 Biol.* 12(3):219-29.